Forget Tech Stocks: The Telehealth Stock That's Riding the AI Wave Better Than Big Tech

Oscar Health has scaled its individual-market membership to roughly 2 million (from ~200k in 2019) and is positioning itself as a tech-first insurer deploying AI (Oswell) and complimentary telehealth, but remains unprofitable. Faster-than-expected healthcare cost growth in 2025 led to claims outpacing premiums, prompting a ~28% price increase for 2026, while the expiration of ACA subsidies in 2026 creates clear near-term membership risk. Management expects at least $12 billion in revenue this year against a market capitalization under $4 billion, implying potential valuation upside if repricing restores profitability.

Analysis

Market structure: The immediate winners are tech-first insurers and AI/telehealth vendors (Oscar Health, select digital care platforms, and AI suppliers such as NVDA indirectly), while ACA-dependent regional carriers and providers facing higher negotiated rates are losers. Oscar’s 28% average price increase for 2026 and 2m member scale (from ~200k in 2019) signal growing pricing power where it can reprice; however loss of subsidies materially reduces effective demand and pushes pricing elasticity into play within the next 3–6 months. Net effect: share shifts to operators that can lower medical-loss-ratio (MLR) by 300–500 bps using tech and narrow networks.

Risk assessment: Key tail risks are (1) no subsidy extension leading to >15–25% membership decline in 2026, (2) sustained claims inflation keeping combined ratio >100% into 2026–27, and (3) adverse regulatory action (rate caps or risk-corr adjustments) within 6–12 months. Hidden dependencies include reinsurance pricing and state-level rate approvals; liquidity risk exists if cash burn continues through two poor claim seasons. Catalysts: Congressional action on subsidies (30–90 days), Q1–Q2 2026 enrollment and MLR print, and reported impact of Oswell/AI on claim triage (measurable within 6–12 months).

Trade implications: Tactical direct play is a modest long in OSCR sized to conviction (2–3% portfolio) with an 12–24 month horizon to capture margin normalization; hedge with short exposure to large-cap, low-tech insurers (e.g., long OSCR, short UNH ~1:0.6) to neutralize market beta. Use options for asymmetric upside: buy 18–24 month LEAPS calls (~25–35% OTM) sized to 0.5–1% portfolio or sell 15–20% OTM cash‑secured puts to collect premium if comfortable owning. Rotate away from mid-cap ACA-dependent carriers unless subsidy visibility improves within 60 days.

Contrarian angles: The market is overweighting a one-time membership shock and underweighting structural upside from tech-driven MLR improvements and cross-sell (Oscar’s platform monetization). At sub-$4B market cap vs ~$12B revenue guidance, implied revenue multiple (~0.33x) prices in prolonged unprofitability — if Oscar restores combined ratio <100% in 2026, upside could be 2x+ over 12–24 months. Risk: aggressive repricing could improve member pool health (positive selection) or accelerate defections; monitor membership churn >10% as a sell trigger.

Key Decisions for Investors

• Establish a 2–3% long position in OSCR common stock with a 12–24 month horizon; set a tactical stop-loss at 25% below entry and a base target to double (100% upside) if combined ratio falls below 100% or subsidies are extended within 6 months.
• Purchase 18–24 month LEAPS calls on OSCR sized to 0.5–1% of portfolio (25–35% OTM) for asymmetric upside; alternatively sell cash‑secured puts 15–20% OTM to accumulate stock at a discount if willing to own.
• Implement a relative-value pair: long OSCR 1.5% of portfolio and short UNH 1.0% (or equivalent large-cap insurer) to isolate idiosyncratic execution risk; reassess after Q1 2026 enrollment data and if OSCR MLR improvement >300 bps realize profits.
• If federal/legislative clarity on ACA subsidies is not achieved within 60 days (market-implied extension probability <50% or headline coverage drop >10% in enrollment prints), reduce OSCR exposure by 50% and redeploy to NVDA and telehealth platform names benefiting from AI-driven cost takeout.